First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)
National Institutes of Health
Description
The purpose of this Notice of Funding Opportunity (NOFO) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs, or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The NOFO will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase II studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drugs impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The NOFO also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding for further clinical development as FDA-approved treatments. A key aspect of this NOFO is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.
Award amount
Varies, see official page
Eligibility
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Who can apply: Schools & Colleges, Government & Tribal, For-Profit Businesses, Nonprofits, Small Businesses
Substance Abuse and Mental Health Services Adminis
Award
Varies
Deadline
TBA
The purpose of this program is to support organizations in mobilizing and connecting community resources to increase access to long-term recovery support for people with substance use disorders and co-occurring substance use and mental disorders.
Community and Economic DevelopmentHealth and MedicalMental Health
The purpose of the R01 grant program is to (1) improve understanding of the risks and conditions associated with occupational diseases and injuries, (2) identify and evaluate methods to reduce risks and prevent or minimize exposure to hazardous workplace conditions, and (3) translate scientific findings into practical prevention strategies, interventions, and products that reduce work-related illnesses and injuries. The Research Project Grant (R01) supports a discrete, specified research project in scientific areas that reflect the investigator's expertise and interests and that align with the mission of NIOSH. Applicants must concisely describe the occupational health problem their proposal addresses and explain how the proposed research activities will lead to outputs that help address this problem. Applicants should clearly describe the expected impacts of the proposed research, both during the project period and beyond.
This Notice of Funding Opportunity (NOFO) supports research to develop, implement, monitor, and evaluate technology-driven and cost-effective tools that reduce the global human rabies burden. It also measures progress toward canine rabies elimination, with an emphasis on high-burden countries. Priority research areas include:
Electronic systems for tracking human and dog rabies vaccinations. Managing human rabies exposure investigations. Enhancing rabies laboratory information management systems. Modeling the economic impact of dog-mediated rabies interventions. Estimating rabies-susceptible dog populations. The research is intended to generate data-driven strategies that help accelerate progress toward global canine rabies elimination and protect public health.
This notice of funding opportunity (NOFO) will help build a workforce that's prepared to collect and use high-quality cancer data. This work is essential to understand the impact of cancer and inform public health action, research, and policy.
This NOFO will support the National Program of Cancer Registries (NPCR) by:
Strengthening the cancer surveillance workforce. Improving NPCR cancer data quality and completeness. Promoting the value and use of NPCR cancer surveillance data. The recipient will support certified Oncology Data Specialists (ODS) and other cancer surveillance professionals with education, credentialing, and professional development. These activities are intended to ensure the cancer surveillance workforce has the knowledge, skills, and resources to meet emerging needs and new technologies.
The recipient will develop, maintain, and advance best practices, tools, and partnerships that support NPCR priorities and ensure timely, complete, and high-quality NPCR cancer surveillance data. This includes improving access to the expertise of ODS through technical assistance and guidance for NPCR registries and staff.
In addition, the recipient will strengthen collaboration and communication strategies to promote the value and use of NPCR cancer surveillance data. The goal of these efforts is to help more people recognize that NPCR cancer surveillance data is a valuable resource for cancer research and public health decision-making.
As a cooperative agreement, CDC will work closely with the recipient to provide technical assistance, support coordination with NPCR and partners, monitor progress, and help ensure a prepared cancer surveillance workforce that can meet current and future public health needs.